JUNS · XBRL financial data
Jupiter Neurosciences financial statements, every quarter
The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (JUNS's year ends in late December)
| In thousands of dollars | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | †Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | year only | 19 | 24 |
| Cost of goods and services sold | — | — | — | — | — | year only | 4 | 3 |
| Gross profit | — | — | — | — | — | year only | 14 | 21 |
| Research and development | 92 | 201* | 467 | 759 | 817 | 44* | 411 | 600 |
| Selling, general and administrative | — | — | — | — | — | year only | 1,566 | 2,164 |
| General and administrative | 402 | 1,257* | 1,071 | 1,505 | 1,480 | 2,783* | 1,566 | 2,164 |
| Total operating expenses | 494 | 1,458* | 1,538 | 2,265 | 2,297 | 2,826* | 1,977 | 2,764 |
| Operating income (loss) | (494) | (1,458)* | (1,538) | (2,265) | (2,297) | (2,809)* | (1,963) | (2,743) |
| Interest income | 0 | 5* | 10 | 13 | 10 | — | 18 | 10 |
| Interest expense | 107 | 31* | 1 | 1 | 1 | 62* | 119 | 91 |
| Net income (loss) | (591) | (1,528)* | (1,529) | (2,253) | (2,288) | (2,575)* | (2,062) | (2,274) |
| Earnings per share, basic USD per share | (0.02) | (0.05)* | (0.05) | (0.07) | (0.07) | (0.07)* | (0.06) | (4.08) |
| Earnings per share, diluted USD per share | (0.02) | (0.06)* | (0.05) | (0.07) | (0.07) | (0.07)* | (0.06) | (4.08) |
| Weighted average shares, basic thousands of shares | 31,066 | 29,966* | 33,104 | 33,181 | 34,040 | 38,141* | 35,256 | 558 |
| Weighted average shares, diluted thousands of shares | 31,066 | 26,943* | 33,104 | 33,181 | 34,040 | 38,141* | 35,256 | 558 |
- † Share count changed about 1/47 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal quarters (JUNS's year ends in late December)
| In thousands of dollars | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | †Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | 0 | 3,770 | 2,706 | 1,878 | 724 | 3,789 | 2,363 | 1,522 |
| Accounts receivable | — | — | — | — | — | 3 | — | 10 |
| Inventory | — | — | — | — | — | 160 | 148 | 135 |
| Prepaid and other current assets | — | 114 | — | — | — | — | — | — |
| Total current assets | 1 | 4,650 | 3,611 | 2,819 | 1,632 | 4,825 | 3,410 | 2,549 |
| Right-of-use asset | 81 | 70 | 58 | 47 | 35 | 23 | 12 | 220 |
| Total assets | 86 | 6,202 | 4,963 | 3,968 | 2,576 | 5,564 | 3,949 | 3,719 |
| Total current liabilities | 5,681 | 2,009 | 1,890 | 2,628 | 2,519 | 7,396 | 6,732 | 3,879 |
| Lease liability, non-current | 34 | 21 | 9 | — | — | — | — | 205 |
| Total liabilities | 5,837 | 2,030 | 1,898 | 2,628 | 2,519 | 7,396 | 6,732 | 4,085 |
| Accumulated deficit | (24,495) | (26,022) | (27,551) | (29,804) | (32,092) | (34,667) | (36,729) | (39,003) |
| Total stockholders' equity | (5,751) | 4,172 | 3,065 | 1,340 | 57 | (1,832) | (2,783) | (366) |
| Total liabilities and equity | 86 | 6,202 | 4,963 | 3,968 | 2,576 | 5,564 | 3,949 | 3,719 |
| Common shares outstanding (cover page) thousands of shares | 33,104 | 33,104 | 33,104 | 34,833 | 34,426 | 36,281 | 36,281 | 770 |
- † Share count changed about 1/47 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal quarters (JUNS's year ends in late December)
| In thousands of dollars | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | †Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (591) | (1,528)* | (1,529) | (2,253) | (2,288) | (2,575)* | (2,062) | (2,274) |
| Stock-based compensation | 195* | 1,014* | 421 | 462* | 1,071* | 463* | 501 | 491* |
| Net cash from operating activities | (43)* | year only | (1,063) | (828)* | (1,154)* | (2,368)* | (1,432) | (2,295)* |
| Proceeds from issuing common stock | 0* | 100* | — | — | — | — | — | — |
| Net cash from financing activities | 28* | 7,465* | — | — | — | year only | 6 | 1,454* |
| Net change in cash | (15)* | 3,769* | (1,063) | (828)* | (1,154)* | 3,066* | (1,427) | (841)* |
- † Share count changed about 1/47 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Jupiter Neurosciences | 1,522 | 24 | (2,295)* | 770,081 | 0.7 quarters | 10-QJun 30, 2026 |
| Fibrogen | 50,644 | (1,474) | (3,991)* | 4.0M | 22.9 quarters | 10-QJun 30, 2026 |
| Armata Pharmaceuticals | 23,952 | not reported | (8,666)* | 37.2M | 2.8 quarters | 10-QJun 30, 2026 |
| Imunon | 6,864 | not reported | (3,025)* | 5.6M | 2.3 quarters | 10-QJun 30, 2026 |
| Lunai Bioworks | 1,714 | 31* | (1,841)* | 5.0M | 0.9 quarters | 10-KJun 30, 2026 |
| Dare Bioscience | 12,618 | 188 | (6,775)* | 15.3M | 1.9 quarters | 10-QJun 30, 2026 |
| CEL-SCI | 6,527 | not reported | (4,031)* | 17.6M | 1.6 quarters | 10-QJun 30, 2026 |
| Relmada Therapeutics | 11,334 | not reported | (9,606)* | 106.7M | 22.7 quarters | 10-QJun 30, 2026 |
| America Great Health | 29 | 26 | 1.7* | 21.2B | — | 10-QMar 31, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.